Leap Therapeutics IncNASDAQ:LPTX
- LAST PRICE1.1600
- TODAY'S CHANGE (%)0.0100 (0.8696%)
- Bid / Lots1.1600/ 19
- Ask / Lots1.1700/ 53
- Open / Previous Close1.1400 / 1.1500
- Day Range
- 52 Week Range
- Volume188,102
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LPTX |
|---|---|---|
| 09:32 ET | 321 | 1.14 |
| 09:34 ET | 25350 | 1.1425 |
| 09:38 ET | 7700 | 1.13 |
| 09:41 ET | 3205 | 1.13 |
| 09:43 ET | 3982 | 1.13 |
| 09:48 ET | 300 | 1.15 |
| 09:52 ET | 11165 | 1.15 |
| 09:54 ET | 1000 | 1.17 |
| 09:59 ET | 1350 | 1.16 |
| 10:10 ET | 2895 | 1.17 |
| 10:12 ET | 709 | 1.17 |
| 10:14 ET | 100 | 1.17 |
| 10:17 ET | 100 | 1.155 |
| 10:24 ET | 364 | 1.17 |
| 10:26 ET | 6419 | 1.185 |
| 10:30 ET | 4130 | 1.17 |
| 10:32 ET | 200 | 1.17 |
| 10:33 ET | 1300 | 1.17 |
| 10:35 ET | 1000 | 1.17 |
| 10:39 ET | 1833 | 1.155 |
| 10:42 ET | 402 | 1.16 |
| 10:44 ET | 2382 | 1.17 |
| 10:50 ET | 399 | 1.18 |
| 10:53 ET | 1701 | 1.17 |
| 10:55 ET | 4139 | 1.16 |
| 11:00 ET | 1998 | 1.17 |
| 11:06 ET | 3200 | 1.17 |
| 11:08 ET | 600 | 1.17 |
| 11:09 ET | 1200 | 1.17 |
| 11:11 ET | 2390 | 1.18 |
| 11:13 ET | 230 | 1.18 |
| 11:18 ET | 233 | 1.19 |
| 11:22 ET | 100 | 1.19 |
| 11:24 ET | 100 | 1.18 |
| 11:26 ET | 588 | 1.18 |
| 11:29 ET | 100 | 1.17 |
| 11:31 ET | 158 | 1.175 |
| 11:33 ET | 4900 | 1.17 |
| 11:36 ET | 300 | 1.16 |
| 11:42 ET | 2975 | 1.1601 |
| 11:47 ET | 100 | 1.1653 |
| 12:02 ET | 100 | 1.1686 |
| 12:05 ET | 200 | 1.165 |
| 12:07 ET | 600 | 1.16 |
| 12:18 ET | 5733 | 1.16 |
| 12:23 ET | 200 | 1.165 |
| 12:27 ET | 5800 | 1.16 |
| 12:32 ET | 100 | 1.1686 |
| 12:34 ET | 100 | 1.165 |
| 12:38 ET | 100 | 1.16 |
| 12:39 ET | 100 | 1.16 |
| 12:41 ET | 200 | 1.16 |
| 12:43 ET | 100 | 1.16 |
| 12:45 ET | 200 | 1.16 |
| 12:48 ET | 400 | 1.16 |
| 12:50 ET | 600 | 1.16 |
| 12:52 ET | 200 | 1.17 |
| 12:54 ET | 200 | 1.16 |
| 12:56 ET | 100 | 1.16 |
| 12:57 ET | 300 | 1.16 |
| 01:12 ET | 300 | 1.16 |
| 01:15 ET | 300 | 1.169 |
| 01:24 ET | 550 | 1.16 |
| 01:28 ET | 100 | 1.165 |
| 01:30 ET | 100 | 1.16 |
| 01:32 ET | 200 | 1.165 |
| 01:33 ET | 700 | 1.165 |
| 01:39 ET | 3840 | 1.17 |
| 01:53 ET | 1422 | 1.18 |
| 01:55 ET | 4083 | 1.185 |
| 01:57 ET | 778 | 1.18 |
| 02:00 ET | 100 | 1.179 |
| 02:02 ET | 110 | 1.175 |
| 02:06 ET | 2212 | 1.17 |
| 02:08 ET | 410 | 1.17 |
| 02:15 ET | 1200 | 1.17 |
| 02:29 ET | 6200 | 1.17 |
| 02:31 ET | 100 | 1.17 |
| 02:33 ET | 2142 | 1.175 |
| 02:36 ET | 19798 | 1.18 |
| 02:45 ET | 845 | 1.18 |
| 02:47 ET | 2162 | 1.175 |
| 02:51 ET | 5100 | 1.175 |
| 03:00 ET | 8137 | 1.16 |
| 03:02 ET | 200 | 1.16 |
| 03:03 ET | 100 | 1.16 |
| 03:07 ET | 100 | 1.16 |
Jun 27, 2022
Leap Therapeutics to Host Virtual R&D Day on July 12, 2022, from 7:00AM ET on Monday Jun 27, 2022 by PR Newswire
7:00AM ET on Monday Jun 27, 2022 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Leap Therapeutics Inc | 101.6M | -2.1x | --- |
Summit Therapeutics Inc | 98.1M | -1.0x | --- |
Checkpoint Therapeutics Inc | 100.8M | -1.3x | --- |
Enochian Biosciences Inc | 102.2M | -2.4x | --- |
Brainstorm Cell Therapeutics Inc | 100.7M | -4.3x | --- |
Achilles Therapeutics PLC | 102.7M | -1.5x | --- |
Company Information
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.
Contact Information
- Headquarters
- 47 Thorndike St Ste B1-1CAMBRIDGE, MA, United States 02141-1799
- Phone
- 617-252-4343
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Christopher Mirabelli
- Chief Financial Officer, Treasurer, Secretary, Director
- Douglas Onsi
- Chief Operating Officer
- Augustine Lawlor
- Vice President, Head - Regulatory Affairs and Quality
- Christine Granfield
- Chief Manufacturing Officer
- Mark O'Mahony
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $101.6M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 88.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-0.55 |
Book Value | $1.22 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 90.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,812.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
